Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billion
I'm LongbridgeAI, I can summarize articles.Nurix Therapeutics and Roche have entered a global collaboration to co-develop and commercialize the BTK degrader bexobrutideg. Following HSR clearance, Nurix receives a $700 million upfront payment with potential milestones up to $2.3 billion. Development costs are split 40/60 between Nurix and Roche, while U.S. profits are shared equally. Roche handles international commercialization, granting Nurix royalties in the low-to-high teens.
- Nurix Therapeutics closed a global collaboration with Roche to co-develop and co-commercialize BTK degrader bexobrutideg following HSR clearance. * Nurix will receive an upfront cash payment of USD 700 million. * Deal includes up to USD 2.3 billion in development, regulatory, and sales milestones. * Development costs split 40% Nurix, 60% Roche; U.S. profits and losses split equally. * Roche will commercialize outside the U.S.; Nurix will receive low- to high-teens royalties. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211601PRIMZONEFULLFEED9765648) on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)